Back to search results

PRE-I-SPY Phase I/Ib Oncology Platform Program

Abroad (travel likely)RecruitingPHASE1

Conditions

HER2-positive Breast Cancer · Metastatic Cancer · Metastatic Breast Cancer · Metastatic · HER2-positive Metastatic Breast Cancer · HER2 Mutation-Related Tumors · HER-2 Protein Overexpression · HER2-negative Breast Cancer · Triple Negative Breast Cancer · HR Positive · Hormone Receptor-positive Breast Cancer · Estrogen Receptor Positive Tumor · Progesterone Receptor-positive Breast Cancer · Hormone Receptor Negative Breast Carcinoma · Solid Tumor · Solid Tumor, Adult · Solid Carcinoma · HER2 Low Breast Cancer · HER2 Low Breast Carcinoma · ER Positive Breast Cancer · PR-positive Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States

    Contact: Study coordinator (Anethea Tolliver) · anetheatolliver@uabmc.edu · 205-644-9896
    Contact: Study coordinator (Lindsey M Waldheim) · lwaldheim@uabmc.edu
    Contact: Principal Investigator (Erica Stringer-Reasor, MD)
    Nusrat Jahan, MD (Sub-investigator)
    Katia Khoury, MD (Sub-investigator)
    Gabrielle Rocque, MD (Sub-investigator)

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Jennifer Childress, RN) · jennifer.childress@moffitt.org · 813-745-0578
    Contact: Principal Investigator (Hyo Han, MD)

  • The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Clara Duarte) · vqq5698@bsd.uchicago.edu · 773-834-5727
    Contact: Principal Investigator (Nan Chen, MD)
    Rita Nanda, MD (Sub-investigator)

  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States

    Contact: Study coordinator (Clara Duarte) · vqq5698@bsd.uchicago.edu · 773-834-5727
    Contact: Principal Investigator (Nan Chen, MD)

  • UChicago Medicine Orland Park, Orland Park, Illinois, United States

    Contact: Study coordinator (Clara Duarte) · vqq5698@bsd.uchicago.edu · 773-834-5727
    Contact: Principal Investigator (Nan Chen, MD)

  • University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Katie Vaughn, RN) · schro811@umn.edu · 612-624-6968
    Contact: Study coordinator (Erin Rogers) · roge0507@umn.edu
    Contact: Principal Investigator (David Potter, MD, PhD)
    Doug Yee, MD (Sub-investigator)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Heather Walker, MPH, CCRP) · HKWalker@mdanderson.org · 832-564-8343
    Contact: Study coordinator (Julia Moore, RN) · jmoore@mdanderson.org
    Contact: Principal Investigator (Paula R Pohlmann, MD, MSc, PhD)
    Contact: Principal Investigator (Funda Meric-Bernstam, MD)
    Debasish Tripathy, MD (Sub-investigator)
    Jason A Mouabbi, MD (Sub-investigator)
    Bora Lim, MD (Sub-investigator)
    Ecaterina E Dumbrava, MD (Sub-investigator)
Study leads

  • Paula R Pohlmann, MD, MSc, PhD

    Principal Investigator

    M.D. Anderson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)